View Dividendこのページの翻訳は実験的なもので、現在開発中です。フィードバックをお待ちしております!Mediplantex National Pharmaceutical マネジメントマネジメント 基準チェック /04現在、CEO に関する十分な情報がありません。主要情報 最高経営責任者n/a報酬総額CEO給与比率n/aCEO在任期間no dataCEOの所有権n/a経営陣の平均在職期間データなし取締役会の平均在任期間データなし経営陣の近況Mediplantex National Pharmaceutical Joint Stock Company, Annual General Meeting, Jun 26, 2024May 24すべての更新を表示Recent updatesInvestor sentiment improves as stock rises 20% Jun 13Mediplantex National Pharmaceutical Joint Stock Company, Annual General Meeting, Jun 26, 2024May 24First quarter 2024 earnings released: EPS: ₫309 (vs ₫89.00 in 1Q 2023) Apr 20Full year 2023 earnings released: EPS: ₫954 (vs ₫678 in FY 2022) Jan 25New major risk - Earnings quality Oct 31Second quarter 2023 earnings released: EPS: ₫306 (vs ₫276 in 2Q 2022) Jul 25Investor sentiment deteriorates as stock falls 17% Jul 17Upcoming dividend of ₫500 per share at 1.0% yield Jul 04First quarter 2023 earnings released Apr 23Investor sentiment improves as stock rises 18% Apr 14Investor sentiment improves as stock rises 20% Mar 03Full year 2022 earnings released: EPS: ₫678 (vs ₫597 in FY 2021) Feb 04Third quarter 2022 earnings released: EPS: ₫363 (vs ₫290 in 3Q 2021) Oct 25Second quarter 2022 earnings released: EPS: ₫276 (vs ₫496 in 2Q 2021) Jul 23Inaugural dividend of ₫250 per share Jul 18First quarter 2022 earnings released: ₫796 loss per share (vs ₫496 profit in 1Q 2021) Apr 27New 90-day high: ₫42,000 Oct 15CEO(最高経営責任者Mediplantex National Pharmaceutical CEOがいない、あるいは彼らに関するデータがない。View Ownership